Home/Filings/3/0001144204-19-035848
3//SEC Filing

Sofinnova HealthQuest Partners, L.P. 3

Accession 0001144204-19-035848

CIK 0001447362other

Filed

Jul 23, 8:00 PM ET

Accepted

Jul 24, 9:19 PM ET

Size

12.4 KB

Accession

0001144204-19-035848

Insider Transaction Report

Form 3
Period: 2019-07-24
Holdings
  • Series F Preferred Stock

    Common Stock (982,785 underlying)
  • Series F Preferred Stock Warrant (right to buy)

    Exercise: $0.01From: 2018-01-12Exp: 2023-01-12Common Stock (11,572 underlying)
  • Series A Preferred Stock

    Common Stock (16,015 underlying)
  • Series E-3 Preferred Stock

    Common Stock (318,842 underlying)
  • Series E-2 Preferred Stock

    Common Stock (358,416 underlying)
  • Convertible Promissory Note

    Common Stock
Kong Garheng
10% Owner
Holdings
  • Series F Preferred Stock Warrant (right to buy)

    Exercise: $0.01From: 2018-01-12Exp: 2023-01-12Common Stock (11,572 underlying)
  • Series E-3 Preferred Stock

    Common Stock (318,842 underlying)
  • Series F Preferred Stock

    Common Stock (982,785 underlying)
  • Convertible Promissory Note

    Common Stock
  • Series A Preferred Stock

    Common Stock (16,015 underlying)
  • Series E-2 Preferred Stock

    Common Stock (358,416 underlying)
Footnotes (3)
  • [F1]All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration at a rate of one share of Common Stock for each 1.219 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
  • [F2]The principal amount of the Convertible Promissory Note held by the designated Reporting Person is $1,027,882. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") will automatically convert into the number of shares of Common Stock that is equal to the Conversion Amount as of the closing date divided by 80% of the IPO price per share.
  • [F3]The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein.

Issuer

CASTLE BIOSCIENCES INC

CIK 0001447362

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001579382

Filing Metadata

Form type
3
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 9:19 PM ET
Size
12.4 KB